Boston Scientific Corp (BSX) Financial Statements

The company's 15.9% YoY revenue growth is a strong indicator of momentum, comfortably exceeding the double-digit threshold for consistent growth. The 18.0% operating margin is a key positive, suggesting the business is achieving operating leverage where revenue growth outpaces expense growth. This is a favourable sign for profitability scaling. Free cash flow generation, however, presents a more nuanced picture. A 3.5% FCF yield, while positive, is below the framework's >10-15% FCF margin benchmark, indicating conversion could be stronger relative to its market cap. The balance sheet appears healthy for its industry, with a Debt/Equity ratio of 0.47, which is below the cautionary threshold of 1.0x Debt/EBITDA implied by the framework. An ROE of 12.0% is solid but does not meet the framework's high bar of sustainably exceeding 15-20%. The primary concern for a value investor is valuation context; a P/E of 35.7 and the current price imply high expectations for continued premium growth and margin expansion, leaving little room for error. The financial quality is adequate but not uniformly strong across all framework metrics. Analysis based on data as of 2024-05-15.